Recent Quotes (30 days)

You have no recent quotes
chg | %

Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for AMRN
3.39
+0.11 (3.35%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.27 - 3.42
52 week 2.81 - 4.47
Open 3.32
Vol / Avg. 2.75M/1.27M
Mkt cap 918.28M
P/E     -
Div/yield     -
EPS -0.27
Shares 270.88M
Beta 0.66
Inst. own 41%
Nov 1, 2017
Q3 2017 Amarin Corporation PLC Earnings Call - Webcast
Sep 26, 2017
Amarin Corporation PLC at Cantor Fitzgerald Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -22.86% -66.38%
Operating margin -17.84% -50.45%
EBITD margin - -49.88%
Return on average assets -25.78% -50.76%
Return on average equity - -
Employees 215 -
CDP Score - -

Address

Upper Pembroke Pembroke House 2, South Lotts Road
DUBLIN, FK7 9JQ
Ireland
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Officers and directors

Lars G. Ekman M.D., Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 56
Bio & Compensation  - Reuters
Michael Wayne Kalb CPA Chief Financial Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Joseph T. Kennedy J.D. Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Age: 53
Bio & Compensation  - Reuters
Michael J. Farrell Vice President - Finance (principal accounting officer and principal financial officer)
Age: 37
Bio & Compensation  - Reuters
Craig B. Granowitz M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Mark W. Salyer Chief Commercial Officer
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 54
Bio & Compensation  - Reuters